Vertex Pharmaceuticals's top three insider shareholders as of August 29, 2026 are Reshma Kewalramani (Ceo President, 98.28K shares), Stuart A Arbuckle (Evp, Coo, 63.37K shares), Amit Sachdev (Evp Chief Patient Ext Af Off, 55.57K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Reshma Kewalramani | Ceo President | 98,278 | 0 | 98,278 | 16.3% | 03 Mar, 2026 |
| 2 | Amit Sachdev | Evp Chief Patient Ext Af Off | 66,512 | 0 | 66,512 | 11.1% | 23 Jul, 2026 |
| 3 | Stuart A Arbuckle | Evp, Coo | 63,368 | 0 | 63,368 | 10.5% | 02 Jul, 2025 |
| 4 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | 53,572 | 0 | 53,572 | 8.9% | 23 Jul, 2026 |
| 5 | Charles F Jr Wagner | Evp, Co Fo | 47,042 | 0 | 47,042 | 7.8% | 26 Feb, 2026 |
| 6 | Bruce I Sachs | Director | 39,000 | 0 | 39,000 | 6.5% | 31 Aug, 2026 |
| 7 | Jeffrey M Leiden | Executive Chairman | 34,797 | 0 | 34,797 | 5.8% | 26 Feb, 2026 |
| 8 | David Altshuler | Evp, Chief Scientific Officer | 34,477 | 0 | 34,477 | 5.7% | 26 Jan, 2026 |
| 9 | Bastiano Sanna | Evp, Cell Genetic Therapies | 32,038 | 0 | 32,038 | 5.3% | 09 May, 2023 |
| 10 | Joy Liu | Evp And Chief Legal Officer | 19,131 | 0 | 19,131 | 3.2% | 06 Jul, 2026 |
| 11 | Edward Morrow Iii Atkinson | Evp, Chief Technical Ops. Off. | 18,432 | 0 | 18,432 | 3.1% | 26 Feb, 2026 |
| 12 | Carmen Bozic | Evp And Cmo | 15,337 | 0 | 15,337 | 2.6% | 30 Jun, 2026 |
| 13 | Jonathan Biller | Evp And Chief Legal Officer | 13,659 | 0 | 13,659 | 2.3% | 26 Feb, 2026 |
| 14 | Kristen Ambrose | Svp Chief Accounting Officer | 11,624 | 0 | 11,624 | 1.9% | 01 Sep, 2026 |
| 15 | Duncan Mckechnie | Evp, Chief Commercial Officer | 11,001 | 0 | 11,001 | 1.8% | 07 Jul, 2026 |
| 16 | Alan M Garber | Director | 7,344 | 0 | 7,344 | 1.2% | 05 May, 2026 |
| 17 | Mark E. Bunnage | Evp, Chief Scientific Officer | 7,284 | 0 | 7,284 | 1.2% | 19 May, 2026 |
| 18 | Terrence C Kearney | Director | 6,536 | 0 | 6,536 | 1.1% | 14 Aug, 2023 |
| 19 | Lloyd Carney | Director | 6,315 | 0 | 6,315 | 1.1% | 20 Nov, 2025 |
| 20 | Sangeeta N. Bhatia | Director | 4,924 | 0 | 4,924 | 0.8% | 05 May, 2026 |
| 21 | Diana Mckenzie | Director | 2,378 | 0 | 2,378 | 0.4% | 05 May, 2026 |
| 22 | Nancy Thornberry | Director | 2,109 | 0 | 2,109 | 0.4% | 05 May, 2026 |
| 23 | Yuchun Lee | Director | 1,875 | 0 | 1,875 | 0.3% | 31 Jan, 2023 |
| 24 | Suketu Upadhyay | Director | 1,558 | 0 | 1,558 | 0.3% | 05 May, 2026 |
| 25 | Jennifer Schneider | Director | 1,394 | 0 | 1,394 | 0.2% | 05 May, 2026 |
| 26 | Michel Lagarde | Director | 1,132 | 0 | 1,132 | 0.2% | 10 Oct, 2023 |
| 27 | Margaret G Mcglynn | Director | 178 | 0 | 178 | 0.0% | 03 May, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 28 Aug, 2026 | Kristen Ambrose | Svp Chief Accounting Officer | Acquired A | 5,000 | $0.00 | $0 | 11,624 | Direct |
| 27 Aug, 2026 | Bruce I Sachs | Director | Disposed G | 6,000 | $0.00 | $0 | 39,000 | Direct |
| 21 Jul, 2026 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | Acquired A | 8,251 | $0.00 | $0 | 53,572 | Direct |
| 21 Jul, 2026 | Amit Sachdev | Evp Chief Patient Ext Af Off | Acquired A | 8,251 | $0.00 | $0 | 66,512 | Direct |
| 15 Jul, 2026 | Alan M Garber | Director | Acquired A | 32 | $475.28 | $15.00K | 65 | Direct |
| 15 Jul, 2026 | Bruce I Sachs | Director | Acquired A | 100 | $475.28 | $47.50K | 15,772 | Direct |
| 02 Jul, 2026 | Duncan Mckechnie | Evp, Chief Commercial Officer | Disposed S | 1,541 | $519.00 | $799.78K | 11,001 | Direct |
| 02 Jul, 2026 | Ourania Tatsis | Evp, Chief Reg. Quality Off. | Disposed S | 1,500 | $524.99 | $787.49K | 45,321 | Direct |
| 01 Jul, 2026 | Joy Liu | Evp And Chief Legal Officer | Disposed S | 828 | $502.71 | $416.24K | 19,131 | Direct |
| 26 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 596 | $482.50 | $287.57K | 15,337 | Direct |
| 18 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,020 | $462.17 | $471.41K | 15,933 | Direct |
| 15 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 4,062 | $450.00 | $1.83Mn | 16,953 | Direct |
| 05 Jun, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,745 | $450.00 | $785.25K | 21,015 | Direct |
| 01 Jun, 2026 | Joy Liu | Evp And Chief Legal Officer | Disposed S | 828 | $439.91 | $364.25K | 19,959 | Direct |
| 29 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,974 | $450.00 | $888.30K | 22,760 | Direct |
| 15 May, 2026 | Mark E. Bunnage | Evp, Chief Scientific Officer | Disposed S | 33 | $453.45 | $14.96K | 7,284 | Direct |
| 15 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 1,354 | $453.45 | $613.97K | 24,734 | Direct |
| 12 May, 2026 | Carmen Bozic | Evp And Cmo | Disposed S | 6,988 | $450.00 | $3.14Mn | 26,088 | Direct |
| 01 May, 2026 | Jennifer Schneider | Director | Acquired A | 472 | $0.00 | $0 | 2,190 | Direct |
| 01 May, 2026 | Michel Lagarde | Director | Acquired A | 2,866 | $0.00 | $0 | 2,866 | Direct |